Is this possibly a break-through treatment for diabetes?
AGI-1067 = Is this possibly a new break-through treatment for diabetes? I am one of countless millions upon millions who suffers from diabetes today. I recently found out that a certain company by the name of AtheroGenics, Inc. accidently discovered that one of the side effects of its Phase 3 - FDA study was the discovery that its new class of drug, called AGI-1067, may be able to treat other indications," namely "reducing the risk of getting diabetes by 64% compared to a placebo." If there is any possible drug treatment that might result from further research into this new class of drug called AGI-1067, I and so many others who suffer from diabetes might have a greatly improved quality of life from this new drug. If that company AtheroGenics needs some co-partners, some financial infusions, more diabetic research specialists from your labs or other labs, whatever, it could be very helpful and so greatly appreciated. Not only would this drug if it is brought to market help diabetics everywhere, but I am sure it would also be economically rewarding for any company that helped bring this drug to the market. So it should be a win-win all around. Doctors could better treat those suffering from this horrible disease of diabetes, companies such as yours could assist a struggling company (AtheroGenics) with further intensive research, they could help bring the drug to the attention of other research scientists who could then do more research on this promising drug, and they could more quickly bring this pharmaceutical drug to doctors, hospitals, and patients everywhere.
If anyone out there has the ear of any CEO, or BOD member, or anyone working on research into diabetes and the treatment for diabetes, could you please direct this message to anyone of influence and see if AG1-1067 works and can be made available to us diabetics -soon!
Here is the material that I found: AtheroGenics, Inc. (AGIX) - "based on further analysis, the company believes the new class of drug, called AGI-1067, may be able to treat other indications." "Although the formal primary composite endpoint in ARISE was not met, we believe that the trial generated strong evidence that the use of AGI-1067 will produce tangible clinical benefits for patients with coronary artery disease," said Marc Pfeffer, professor of medicine at Harvard Medical School and one of the principal investigators, said in a statement.